Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ProKidney (PROK)
NASDAQ:PROK
Holding PROK?
Track your performance easily
PROK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.18 - $4.44
Previous Close$1.74
Volume370.91K
Average Volume (3M)687.27K
Market Cap
$507.58M
Enterprise Value$1.52B
Total Cash (Recent Filing)$406.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Apr 01, 2025EPS Estimate
-$0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding291,661,950
10 Day Avg. Volume537,326
30 Day Avg. Volume687,275
Standard Deviation0.23
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-0.49
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.63
Forecast
1Y Price Target
$4.25Price Target Upside151.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
ProKidney News
PremiumCompany Announcements
ProKidney’s Progress in FDA Approval and Financial Health
PremiumCompany Announcements
ProKidney: Investor Update and Phase 3 Program ProgressBulls Say, Bears Say
Bulls Say
Financial PerformanceDiscontinuation of PROACT 2 is expected to result in savings of $150M to $175M, extending the company's cash runway.
Market PotentialRilparencel is a differentiated approach in diabetic CKD with blockbuster potential.
Regulatory ApprovalFDA confirmed that PROACT 1 could be sufficient to support a BLA submission and full approval.
Bears Say
Financial PerformanceThe company’s cash runway stops approximately half a year short of the pivotal readout for the company’s cell therapy treatment aimed at delaying or stopping progression of chronic kidney disease.
Operational StrategyNeed for more de-risking data for the product to increase Street focus and shift sentiment.
Research And DevelopmentThe sample size of the most recent data from the REGEN-007 study is small.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PROK FAQ
What was ProKidney’s price range in the past 12 months?
ProKidney lowest stock price was $1.18 and its highest was $4.44 in the past 12 months.
What is ProKidney’s market cap?
Currently, no data Available
When is ProKidney’s upcoming earnings report date?
ProKidney’s upcoming earnings report date is Apr 01, 2025 which is in 129 days.
How were ProKidney’s earnings last quarter?
ProKidney released its earnings results on Nov 12, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.128 by -$0.012.
Is ProKidney overvalued?
According to Wall Street analysts ProKidney’s price is currently Undervalued.
Does ProKidney pay dividends?
ProKidney does not currently pay dividends.
What is ProKidney’s EPS estimate?
ProKidney’s EPS estimate is -$0.14.
How many shares outstanding does ProKidney have?
ProKidney has 127,968,250 shares outstanding.
What happened to ProKidney’s price movement after its last earnings report?
ProKidney reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.128. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of ProKidney?
Among the largest hedge funds holding ProKidney’s share is EntryPoint Capital, LLC. It holds ProKidney’s shares valued at 33K.
---
ProKidney Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (151.48% Upside)
$4.25 (151.48% Upside)
Blogger Sentiment
Bullish
PROK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.09%
Trailing 12-Months
Company Description
ProKidney
Social Capital Suvretta Holdings Corp III is a blank check company.
---
PROK Company Deck
---
PROK Earnings Call
Q3 2023
0:00 / 0:00
---
PROK Stock 12 Month Forecast
Average Price Target
$4.25
▲(151.48% Upside)
Technical Analysis
Best Analysts Covering PROK
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-35.21%
reiterated a buy rating 3 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -35.21% per trade.
---